Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Katie Pilbeam about their peer review paper on their first clinical trial of proprietary product, AT247, which has been published in the prestigious medical journal Diabetes Care.
In terms of news flow, their first patient has been dosed in a phase 1 clinical trial for their second product, AT278, a new ultra-concentrated rapid insulin.
And their partner INHIBRX has licensed an option to take their liquid formulation of their product to the clinic.